// App-Quantinova.ai

: Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naive prostate cancer: Results from LATITUDE.

Researchers

Presenter

  • Tracy Li

Principal Investigators

  • Conrado Franco-Villalobos

  • Irina Proskorovsky

  • Sonja V Sorensen

  • Namphuong Tran

  • Giri Sulur

  • Kim N. Chi

Medical Centers

  • Janssen Global Services, Raritan, NJ

  • Evidera, St-Laurent, QC, Canada

  • Evidera, Bethesda, MD

  • Janssen Research & Development, Los Angeles, CA

  • BC Cancer Agency, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01715285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved